|
Latest News
August 17, 2011 - Altor BioScience Awarded SBIR Phase I Grant by NCI for Research on its Novel IL-15 Super Agonist for Bladder Cancer
June 28, 2011 - Florida Biologix Announces Manufacturing Agreement with Altor BioScience
June 3, 2011 - Miramar firm showcases South Florida's life-science industry
May 23, 2011 - Altor BioScience Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI to Complete a Second Phase 2 ALI/ARDS Clinical Trial for its Antibody-based Tissue Factor Antagonist, ALT-836
February 16, 2011 - Altor BioScience Awarded SBIR Phase I Grant by NIAID for HIV Research
More News...
|
 |
Technology Platforms
STAR™ Technology Platform: The Company’s proprietary Soluble T-cell Antigen Receptor (STAR™) technology enables the recognition of novel targets on cancerous or virally infected cells which cannot be seen by traditional monoclonal antibodies.
Tissue Factor Antagonists Platform: Monoclonal antibody based antagonists are being explored in clinical development to treat a variety of life-threatening inflammatory diseases and cancer.
IL-15 Platform: IL-15 agonists, antagonists and protein scaffolds are being utilized to create novel immune molecules for treatment of cancer, infections and inflammation.
More on Altor’s Technology...
Product/Clinical Development
Multiple first-in-class product candidates derived from the STAR™ and Tissue Antagonists Platforms are currently in clinical development. Numerous product candidates have completed proof-of-principle studies in animal models and are at preclinical development stage.
More on Product/Clinical Development...
|
|
STAR™ Reagents Available
Altor has launched an exciting new class of innovative products based on its proprietary STAR™ technology. These products enable the detection of novel disease targets presented on the surface of cells and tissues. Altor has also introduced recombinant human tissue factor for use in hemostasis and thrombosis research applications.
More on Research Reagents...
See Article published in BioMarkers in Medicine...
|
